The meeting outlined the evidence that the use of magnetic resonance imaging (MRI) markers as surrogate endpoints in clinical trials of relapsing-remitting multiple sclerosis (MS) is both valid and informative.
In this issue
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given